

Revised Draft Agenda
Biocides Working Group Meeting V-2019
12-20 November 2019

APCP WG: Virtual meeting using WebEx
 EFF, ENV, TOX and ARTFood WGs: ECHA Conference Centre (Annankatu 18)
 Meeting room K325
 Meeting room Marie Curie (MC)
 Meeting room Margot Wallstrom (MW)

Coffee break 11:00-11:30
 Lunch break 13:00-14:00
 Coffee break 15:30-16:00

Tuesday 12 November	10:00-13:00	APCP WG (K325) - WebEx
	14:00-18:00	
Tuesday 12 November	09:00-13:00	EFF WG (MW)
	14:00-18:00	
Wednesday 13 November	09:00-13:00	EFF WG (MW)
	14:00-18:00	
Thursday 14 November	09:00-13:00	EFF WG (MW)
	14:00-16:00	
Thursday 14 November	09:00-13:00	ENV WG (MC - A)
	14:00-18:00	
Friday 15 November	09:00-13:00	ENV WG (MC - A)
	14:00-18:00	
Monday 18 November	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Tuesday 19 November	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 20 November	09:00-13:00	ARTFood WG (MW)
	14:00-16:00	

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 - Administrative issues		
Item 3 - Agreement of the agenda		<i>For agreement</i>
Item 4 - Declarations of potential conflicts of interest in relation to the agenda		
Item 5 - Agreement of the draft minutes from WG-IV-2019		
<ul style="list-style-type: none"> • <i>WG IV 2019_APCP_6-1</i> • <i>WG IV 2019_APCP_6-2</i> • <i>WG IV 2019_APCP_7-3</i> • <i>WG IV 2019_APCP_general</i> 		
Item 6 - Outcome of e-consultations		
Item 7 - Discussion of active substances		eCA
7.1	Glyoxal PT 02, 03, 04 Meeting document: <i>WG V 2019_APCP_7-1</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
7.2	Peroxyoctanoic acid PT 02, 03, 04 Previous meeting(s): WGIII 2019 Meeting documents: <i>WG V 2019_APCP_7-2</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
Item 8 - Discussion of Union Authorisations		eCA
8.1	UA for product family containing Hydrogen peroxide PT 01, 02, 03, 04 Previous meeting(s): WGII 2019 Meeting documents: <i>WG V 2019_APCP_8-1</i> <div style="text-align: right;"><i>For agreement</i></div>	LV
8.2	UA for product family containing propan-2-ol PT 02, 04 Meeting document: <i>WG V 2019_APCP_8-2</i> <div style="text-align: right;"><i>For agreement</i></div>	DE

8.3	UA for product family containing CMIT/MIT PT 06 Meeting document: <i>WG V 2019_APCP_8-3</i> <i>For agreement</i>	FR
8.4	UA for product family containing Peracetic acid PT 02 Meeting document: <i>WG V 2019_APCP_8-4</i> <i>For agreement</i>	UK
8.5	UA for product family containing Hydrogen peroxide PT 02 Meeting document: <i>WG V 2019_APCP_8-5</i> <i>For agreement</i>	UK
Item 9 - Technical and guidance related issues		
Item 10 – AOB		

Efficacy Working Group		
Chair: Katarzyna Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2019		
<ul style="list-style-type: none"> • WG-IV-2019_EFF_6-1 • WG-IV-2019_EFF_6-2 • WG-IV-2019_EFF_6-3 • WG-IV-2019_EFF_Minutes 		<i>For agreement</i>
Item 6 – Discussion of Union Authorisations		eCA
6.1	UA for product family containing propan-2-ol PT 02, 04 Meeting document: <i>WGV2019_EFF_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DE
6.2	UA for product family containing CMIT/MIT PT 06 Meeting document: <i>WGV2019_EFF_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
6.3	UA for product family containing Peracetic acid PT 02 Meeting document: <i>WGV2019_EFF_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	UK
6.4	UA for product family containing Hydrogen peroxide PT 02 Meeting document: <i>WGV2019_EFF_6-4</i> <div style="text-align: right;"><i>For agreement</i></div>	UK
6.5	Early WG of general interest PT 05 Meeting document: <i>WGV2019_EFF_6-5</i> <div style="text-align: right;"><i>For agreement</i></div>	NL

6.6	Early WG of general interest PT 02 Meeting document: <i>WGV2019_EFF_6-6</i> <i>For agreement</i>	BE
Item 7 - Discussion of Active Substances		eCA
7.1	Glyoxal PT 02-04 Meeting document: <i>WGV2019_EFF_7-1</i> <i>For agreement</i>	FR
7.2	Early WG discussion PT 07, 10 Meeting document: <i>WGV2019_EFF_7-2</i> <i>For agreement</i>	DE
7.3	Early WG discussion PT 08 Meeting document: <i>WGV2019_EFF_7-3</i> <i>For agreement</i>	DK
7.4	Early WG discussion PT 02, 04 Meeting document: <i>WGV2019_EFF_7-4</i> <i>For agreement</i>	IT
Item 8 - Technical and guidance related issues		
8.1	Vol. II, Parts B+C – PT19 Meeting documents: <i>WGV2019_EFF_8-1a – validation of AIC test;</i> <i>WGV2019_EFF_8-1b - mosquitos;</i> <i>WGV2019_EFF_8-1c - biting midges;</i> <i>WGV2019_EFF_8-1d - ants;</i> <i>For discussion</i>	AISE/CEF IC DE DK
8.2	Vol. II, Parts B+C – PT11 Meeting document: <i>WGV2019_EFF_8-2</i> <i>For discussion</i>	FR
8.3	Application of the tiered approach to preservatives evaluation Meeting document: <i>WGV2019_EFF_8-3</i> <i>For discussion</i>	DE
8.4	P2S2 tests required to support fungicidal and virucidal claims of hard surface disinfectants for applications with mechanical action Meeting document: <i>WGV2019_EFF_8-4</i> <i>For discussion</i>	FI

8.5	<i>In situ</i> recommendations Meeting document: <i>WGV2019_EFF_8-5</i> <i>For discussion</i>	ECHA
Item 9 – AOB		
9.1	Introducing the Activities Coordination Tool (ACT) <i>For information</i>	ECHA
9.2	Other information & lessons learned Meeting document: <i>WGV2019_EFF_9-2</i> <i>For information</i>	ECHA

Environment Working Group Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2019		
<ul style="list-style-type: none"> • WG-IV-2019_ENV_6-1 • WG-IV-2019_ENV_6-2 • WG-IV-2019_ENV_6-3 • WG-IV-2019_ENV_6-4 • WG-IV-2019_ENV_7-1 • WG-IV-2019_ENV_7-2 • WG-IV-2019_ENV_7-3 • WG-IV-2019_ENV_7-4 • WG-IV-2019_ENV_7-5 • WG-IV-2019_ENV_General_minutes 		<i>For agreement</i>
Item 6 - Discussion of Union Authorisations		eCA
6.1	UA for product family containing propan-2-ol PT 02, 04 Meeting document: <i>WGV2019_ENV_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DE
6.2	UA for product family containing CMIT/MIT PT 06 Meeting document: <i>WGV2019_ENV_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
6.3	UA for product family containing Peracetic acid PT 02 Meeting document: <i>WGV2019_ENV_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	UK
6.4	UA for product family containing Hydrogen peroxide PT 02 Meeting document: <i>WGV2019_ENV_6-4</i> <div style="text-align: right;"><i>For agreement</i></div>	UK

Item 7 - Discussion of Active Substances		eCA
7.1	Glyoxal PT 02-04 Meeting document: <i>WGV2019_ENV_7-1</i> <i>For agreement</i>	FR
7.2	New endpoints for PBO Follow up e-consultation Meeting document: <i>WGV2019_ENV_7-2</i> <i>For agreement</i>	EL
7.3	Bardap 26 – PT 8 (P and T assessment) Follow up WG III 2019 Meeting document: <i>WGV2019_ENV_7-3</i> <i>For agreement</i>	IT
7.4	New endpoints for Dinotefuran Meeting document: <i>WGV2019_ENV_7-4</i> <i>For agreement</i>	NL
Item 8 – Technical and guidance related issues		Presenter
8.1	Overview on guidance Meeting document: <i>WGV2019_ENV_8-1</i> <i>For information</i>	SECR
8.2	Development of the bioaccumulation assessment for air-breathing organisms: use of mammalian toxicokinetic data in bioaccumulation assessment – project update Meeting document: <i>WGV2019_ENV_8-2</i> <i>For information</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGV2019_ENV_9-1</i> <i>For information</i>	SECR
9.2	Update on EUSES <i>For information</i>	SECR
9.3	BPC document on Interpreting the definition of relevant impurities – impacts on ENV assessment TBC <i>For information</i>	SECR
9.4	Development of the bioaccumulation assessment for air-breathing organisms: use of mammalian toxicokinetic data in bioaccumulation assessment – project update Meeting document: <i>WGV2019_ENV_9.4</i> <i>For information</i>	SECR

9.5	Training on assessing endocrine activity using in vitro methods <i>For information</i>	SECR
------------	--	------

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2019		
<ul style="list-style-type: none"> • WG-IV-2019_TOX_6-1 • WG-IV-2019_TOX_6-2 • WG-IV-2019_TOX_7-1 • WG-IV-2019_TOX_7-2 • WG-IV-2019_TOX_7-3 • WG-IV-2019_TOX_Minutes 		<i>For agreement</i>
Item 6 - Discussion of Union Authorisations		eCA
6.1	UA for product family containing propan-2-ol PT 2, 4 Meeting document: <i>WGV2019_TOX_6-1</i>	DE <i>For agreement</i>
6.2	UA for product family containing CMIT/MIT PT 6 Meeting document: <i>WGV2019_TOX_6-2</i>	FR <i>For agreement</i>
6.3	UA for product family containing Peracetic acid PT 2 Meeting document: <i>WGV2019_TOX_6-3</i>	UK <i>For agreement</i>
6.4	UA for product family containing Hydrogen peroxide PT 2 Meeting document: <i>WGV2019_TOX_6-4</i>	UK <i>For agreement</i>
Item 7 - Discussion of Active Substances		eCA
7.1	Glyoxal PT 2-4 Meeting document: <i>WGV2019_TOX_7-1</i>	FR <i>For agreement</i>

7.2	Sulfuryl fluoride PT 8, 18 Meeting document: <i>WGV2019_TOX_7-2</i> <i>For agreement</i>	SE
7.3	Chlorophene – revised assessment PT 2 Meeting document: <i>WGV2019_TOX_7-3</i> <i>For agreement</i>	NO
7.4	Silver containing active substances – need for further information regarding carcinogenicity PT 1, 2, 4, 5, 6, 7, 9, 10, 11 Meeting document: <i>WGV2019_TOX_7-4</i> <i>For agreement</i>	SE
Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGV2019_TOX_8-1</i> <i>For discussion</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGV2019_TOX_9-1</i> <i>For discussion</i>	SECR

ARTFood Ad hoc WG		
Chair: Laura Ruggeri		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 - Technical and guidance related issues		eCA
5.1	Guidance on Estimating Transfer of Biocidal Active Substances into Foods – Professional Uses Meeting document: <i>WGV2019_ARTFOOD_5-1</i>	DE
5.2	Dietary risk assessment for PT 19 with skin application Meeting document: <i>WGV2019_ARTFOOD_5-2</i>	FR

oOo